Two isoforms of HOXA9 function differently but work synergistically in human MLL-rearranged leukemia

Blood Cells, Molecules, and Diseases

Volumn 49, Issue 2, 2012, Pages 102-106

  He, Miao ^a,b   Chen, Ping ^a   Arnovitz, Stephen ^a   Li, Yuanyuan ^a   Huang, Hao ^a   Neilly, Mary Beth ^a   Wei, Minjie ^b   Rowley, Janet D ^a   Chen, Jianjun ^a   Li, Zejuan ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Isoforms; Leukemia

Indexed keywords

BINDING PROTEIN; ISOPROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN HOXA9T; PROTEIN MEIS1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA9; TRANSCRIPTION FACTOR PBX1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; EXON; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INTERACTION; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL; HOXA9 GENE; HOXA9T GENE; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MLL GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOP CODON;

ANIMALS; BASE SEQUENCE; BONE MARROW; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CODON, NONSENSE; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA; MICE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PROTEIN ISOFORMS; RNA, MESSENGER;

EID: 84863848932     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2012.05.003     Document Type: Article

References (36)

1. Barber B.A., Rastegar M. Epigenetic control of Hox genes during neurogenesis, development, and disease. Ann. Anat. 2010, 192:261-274.
2. Shah N., Sukumar S. The Hox genes and their roles in oncogenesis. Nat. Rev. Cancer 2010, 10:361-371.
3. Sitwala K.V., Dandekar M.N., Hess J.L. HOX proteins and leukemia. Int. J. Clin. Exp. Pathol. 2008, 1:461-474.
4. Huang Y., Sitwala K., Bronstein J., et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood 2012, 119:388-398.
5. Schnabel C.A., Jacobs Y., Cleary M.L. HoxA9-mediated immortalization of myeloid progenitors requires functional interactions with TALE cofactors Pbx and Meis. Oncogene 2000, 19:608-616.
6. Hu Y.L., Fong S., Ferrell C., Largman C., Shen W.F. HOXA9 modulates its oncogenic partner Meis1 to influence normal hematopoiesis. Mol. Cell. Biol. 2009, 29:5181-5192.
7. Wang Y., Krivtsov A.V., Sinha A.U., et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010, 327:1650-1653.
8. Lawrence H.J., Christensen J., Fong S., et al. Loss of expression of the Hoxa-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells. Blood 2005, 106:3988-3994.
9. Eklund E. The role of hox proteins in leukemogenesis: insights into key regulatory events in hematopoiesis. Crit. Rev. Oncog. 2011, 16:65-76.
10. Faber J., Krivtsov A.V., Stubbs M.C., et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009, 113:2375-2385.
11. Li Z., Huang H., Li Y., et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically-abnormal AML. Blood 2012, 119:2314-2324.
12. Li Z., Luo R.T., Mi S., et al. Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res. 2009, 69:1109-1116.
13. Andreeff M., Ruvolo V., Gadgil S., et al. HOX expression patterns identify a common signature for favorable AML. Leukemia 2008, 22:2041-2047.
14. Armstrong S.A., Staunton J.E., Silverman L.B., et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 2002, 30:41-47.
15. Bullinger L., Dohner K., Bair E., et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 2004, 350:1605-1616.
16. Kroon E., Krosl J., Thorsteinsdottir U., et al. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 1998, 17:3714-3725.
17. Zeisig B.B., Milne T., Garcia-Cuellar M.P., et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol. Cell. Biol. 2004, 24:617-628.
18. Kim M.H., Chang H.H., Shin C., et al. Genomic structure and sequence analysis of human HOXA-9. DNA Cell Biol. 1998, 17:407-414.
19. Popovic R., Erfurth F., Zeleznik-Le N. Transcriptional complexity of the HOXA9 locus. Blood Cells Mol. Dis. 2008, 40:156-159.
20. Dintilhac A., Bihan R., Guerrier D., Deschamps S., Pellerin I. A conserved non-homeodomain Hoxa9 isoform interacting with CBP is co-expressed with the 'typical' Hoxa9 protein during embryogenesis. Gene Expr. Patterns 2004, 4:215-222.
21. Fujimoto S., Araki K., Chisaka O., et al. Analysis of the murine Hoxa-9 cDNA: an alternatively spliced transcript encodes a truncated protein lacking the homeodomain. Gene 1998, 209:77-85.
22. He L., Thomson J.M., Hemann M.T., et al. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833.
23. Li Z., Lu J., Sun M., et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15535-15540.
24. Mi S., Li Z., Chen P., et al. Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3710-3715.
25. Bach C., Buhl S., Mueller D., et al. Leukemogenic transformation by HOXA cluster genes. Blood 2010, 115:2910-2918.
26. Calvo K.R., Sykes D.B., Pasillas M., Kamps M.P. Hoxa9 immortalizes a granulocyte-macrophage colony-stimulating factor-dependent promyelocyte capable of biphenotypic differentiation to neutrophils or macrophages, independent of enforced meis expression. Mol. Cell. Biol. 2000, 20:3274-3285.
27. Zhang Y., Morrone G., Zhang J., et al. CUL-4A stimulates ubiquitylation and degradation of the HOXA9 homeodomain protein. EMBO J. 2003, 22:6057-6067.
28. Shin J., Park B., Lee S., et al. A short isoform of human cytomegalovirus US3 functions as a dominant negative inhibitor of the full-length form. J. Virol. 2006, 80:5397-5404.
29. Li T.W., Ting J.H., Yokoyama N.N., et al. Wnt activation and alternative promoter repression of LEF1 in colon cancer. Mol. Cell. Biol. 2006, 26:5284-5299.
30. Dotsch V., Bernassola F., Coutandin D., Candi E., Melino G. p63 and p73, the ancestors of p53. Cold Spring Harb. Perspect. Biol. 2010, 2:a004887.
31. Figtree G.A., McDonald D., Watkins H., Channon K.M. Truncated estrogen receptor alpha 46-kDa isoform in human endothelial cells: relationship to acute activation of nitric oxide synthase. Circulation 2003, 107:120-126.
32. Gough P.J., Greaves D.R., Gordon S. A naturally occurring isoform of the human macrophage scavenger receptor (SR-A) gene generated by alternative splicing blocks modified LDL uptake. J. Lipid Res. 1998, 39:531-543.
33. Oakley R.H., Jewell C.M., Yudt M.R., Bofetiado D.M., Cidlowski J.A. The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J. Biol. Chem. 1999, 274:27857-27866.
34. Zaika A.I., Slade N., Erster S.H., et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 2002, 196:765-780.
35. Chang C.P., Shen W.F., Rozenfeld S., et al. Pbx proteins display hexapeptide-dependent cooperative DNA binding with a subset of Hox proteins. Genes Dev. 1995, 9:663-674.
36. Thorsteinsdottir U., Kroon E., Jerome L., Blasi F., Sauvageau G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol. Cell. Biol. 2001, 21:224-234.